The concern that Ozempic and similar weight-loss medications "melt muscle" has become one of the most persistent fears surrounding GLP-1 treatment. There is a real issue underneath the phrase: substantial weight loss with semaglutide, tirzepatide and related incretin therapies can include measurable reductions in lean tissue. The evidence does not support the stronger claim that these medications uniquely destroy skeletal muscle, nor does it support treating every decline in DXA-measured lean mass as an equivalent decline in functional muscle.
That distinction matters because body composition, skeletal muscle mass, strength and physical function are related but different outcomes. As incretin-based treatments become more common, understanding the difference between those measurements is becoming increasingly important for patients, clinicians and researchers.
Does Ozempic Actually Cause Muscle Loss?
Clinical studies do show that semaglutide and other incretin-based therapies can be associated with reductions in lean mass during weight loss. The difficulty begins when the term "lean mass" is automatically translated into "muscle."
Dual-energy X-ray absorptiometry, commonly known as DXA, separates body composition into broad compartments that include fat mass, bone mineral and lean soft tissue. Skeletal muscle is part of that lean compartment, but so are water, organs, connective tissue and other non-fat tissues. DXA therefore does not directly establish that every pound of measured lean-mass loss represents a pound of skeletal-muscle protein.
Hydration can also influence DXA measurements. Controlled studies have shown that dehydration, rehydration, water intake, glycogen changes and related shifts can alter measured lean-tissue values even when actual muscle protein has not changed by the same amount. [1][2] None of this makes DXA an unreliable tool. It remains a well-established method for evaluating body composition. It does mean that its results need to be described with greater precision than the phrase "muscle loss" usually allows.
What Did the SURMOUNT-1 Tirzepatide Study Find?
One of the strongest available body-composition datasets comes from the SURMOUNT-1 trial of tirzepatide, the active ingredient in Zepbound. Tirzepatide is technically a dual GIP and GLP-1 receptor agonist rather than a GLP-1 receptor agonist alone, a distinction confirmed in FDA labeling. [3]
A DXA substudy followed 160 participants from the larger 2,539-person SURMOUNT-1 trial who completed body-composition scans at baseline and again at week 72. Participants receiving tirzepatide lost substantially more body weight than those receiving placebo. Body weight declined by 21.3% with tirzepatide compared with 5.3% with placebo. Fat mass fell by 33.9% with tirzepatide and 8.2% with placebo, while lean mass declined by 10.9% and 2.6%, respectively. [4]
The proportional result is especially useful for understanding the muscle-loss debate. Approximately 75% of the weight lost was fat mass and 25% was lean mass in both the tirzepatide and placebo groups. [4] Lean tissue was therefore genuinely lost, but fat still accounted for the majority of total weight reduction.
This does not support the idea that tirzepatide primarily strips muscle away while leaving fat intact. It supports a more measured conclusion: substantial weight loss includes some lean-tissue loss, while fat loss remains the dominant component.
Is Losing 25% of Weight as Lean Mass Unusual?
Not necessarily. Lean-mass loss can occur during substantial weight loss even in the absence of GLP-1 medications. When body weight falls significantly, the body does not selectively remove only stored fat. Some non-fat tissue commonly changes as well.
A major 2026 systematic review and meta-analysis directly compared incretin-based therapies with intensive lifestyle interventions. The analysis included 20 randomized controlled trials involving 15,782 participants. [5] Across the included studies, lean mass represented approximately 35.2% of total weight lost with semaglutide, 25.4% with tirzepatide and 26.8% with liraglutide. [5]
When incretin therapy was compared with lifestyle intervention overall, the difference in the proportion of weight lost as lean mass was not statistically significant. [5] This finding complicates the idea that GLP-1 medications create a uniquely catastrophic muscle-loss problem. Major weight reduction itself creates a challenge around lean-mass preservation, whether that weight loss occurs through medication, lifestyle intervention or some combination of both.
Does Semaglutide Cause More Lean-Mass Loss Than Tirzepatide?
The 2026 meta-analysis estimated a larger lean-mass share of total weight loss for semaglutide than for tirzepatide, approximately 35.2% compared with 25.4%. Liraglutide was approximately 26.8%. [5]
Those numbers should not be treated as a simple head-to-head ranking of which drug "destroys more muscle." The underlying trials differed in participant populations, treatment duration, total weight loss achieved, body-composition methodology and study design. A meta-analysis can identify broad patterns across studies, but it does not convert separately conducted trials into one perfectly controlled comparison between drugs.
The more defensible conclusion is that meaningful lean-mass loss has been observed across several incretin therapies, while the amount varies among studies and should be interpreted within the context of the specific trial.
What Did the SEMALEAN Study Find About Semaglutide?
The SEMALEAN study provides one of the clearest examples of why muscle quantity and muscle function should not be treated as interchangeable.
The prospective real-world study enrolled 115 adults with severe obesity who were treated with semaglutide 2.4 mg, with 106 participants completing follow-up. Participants lost approximately 10% of their body weight by month seven and 13% by month 12. Lean mass declined by roughly 3 kilograms during the first seven months and then stabilized. [6]
If body composition were the only outcome measured, that result could easily be interpreted as evidence of worsening muscle health. The functional data told a more complicated story. Handgrip strength increased by approximately 4.5 kilograms by month 12, while the prevalence of sarcopenic obesity declined from 49% to 33%. [6]
This does not mean lean-mass loss is irrelevant. It demonstrates that one body-composition number cannot represent the entire muscular system. A person can experience a reduction in measured lean mass while simultaneously improving strength and other indicators of muscle function.
How Can Lean Mass Decline While Strength Improves?
Muscle health depends on more than size alone. Strength is influenced by muscle quantity, neural activation, muscle quality, fiber characteristics, physical activity, biomechanics and other physiological factors.
Someone with severe obesity may also begin treatment with a relatively high absolute amount of lean tissue because carrying a larger body requires more muscle and supporting tissue. As body weight declines, some reduction in lean mass may reflect physiological adaptation rather than pathological muscle wasting.
This is one reason modern approaches to sarcopenia increasingly emphasize strength and physical performance alongside measures of muscle quantity. SEMALEAN is especially useful because the same participants demonstrated early lean-mass decline followed by measurable improvement in handgrip strength. [6] If every kilogram of DXA lean mass lost automatically represented an equivalent loss of functional muscle, that pattern would be difficult to reconcile.
Why Lean Mass Is Not the Same Thing as Muscle
For consumers trying to understand the current debate, this distinction is one of the most important facts in the entire subject.
Lean mass refers broadly to the tissue in the body that is not classified as fat or bone mineral within a given body-composition model. Skeletal muscle is one component of that compartment, but it is not the entire compartment.
DXA-derived appendicular lean soft tissue, which measures lean tissue in the arms and legs, is often used as a proxy for skeletal muscle because much of that tissue is muscle. A proxy, however, is not the same thing as a direct measurement. MRI and CT imaging can provide more direct information about skeletal-muscle size and distribution, while functional tests such as grip strength and walking performance provide different information again.
The evidence therefore forms a hierarchy that is easy to flatten in headlines. Body weight, fat mass, lean mass, appendicular lean mass, skeletal-muscle mass, muscle quality, strength, physical performance and sarcopenia are connected concepts, but they are not synonyms.
Can Hydration Change a DXA Lean-Mass Reading?
Yes. This is particularly relevant during rapid weight loss because water and glycogen can shift alongside changes in fat and tissue mass.
A controlled study published in the European Journal of Applied Physiology found that dehydration and subsequent glycogen supercompensation changed DXA measurements of lean tissue mass. [1] Another controlled study found that drinking 500 milliliters of water before a DXA scan increased measured lean mass by approximately half a kilogram on average. [2] Research involving muscle creatine, glycogen and water manipulation has also shown that DXA lean-mass estimates can change under conditions where corresponding changes in actual muscle protein would be unlikely. [7]
These findings do not eliminate or explain away the lean-mass changes observed in weight-loss trials. They show why the statement "DXA measured three kilograms less lean mass" should not automatically become "three kilograms of skeletal muscle was destroyed."
Is Muscle Loss Still a Real Concern for People Taking GLP-1 Drugs?
Yes. Rejecting exaggerated claims does not mean dismissing the underlying clinical issue.
Muscle preservation may be especially important for older adults, people who begin treatment with low muscle mass or reduced strength, people losing very large amounts of weight and anyone already at elevated risk of frailty or sarcopenia. Major weight reduction can provide important metabolic and health benefits while simultaneously creating a need to preserve functional tissue.
The central question is therefore not whether lean-mass loss occurs. It does. The more clinically useful question is whether skeletal muscle, strength and physical function are being preserved adequately for the individual patient. Answering that requires more than watching total body weight or a single body-composition measurement.
What Helps Preserve Lean Mass During Weight Loss?
Resistance training has some of the strongest current evidence.
In the 2026 comparative meta-analysis, lifestyle interventions that included resistance training had a substantially smaller proportion of total weight loss coming from lean mass, approximately 17.5%, compared with higher proportions observed across several incretin-therapy groups. [5]
That finding does not establish one universal exercise prescription for every GLP-1 user. It does support the broader principle that exposing muscle to regular resistance while losing weight helps preserve lean tissue.
Protein intake is also biologically relevant because dietary amino acids support muscle protein synthesis, although the current GLP-1-specific literature does not establish one universal protein target appropriate for every patient. Age, baseline muscle status, calorie intake, nutritional adequacy, physical activity and the rate and magnitude of weight loss can all influence body composition.
For that reason, there is not enough evidence to justify one universal protein prescription or training plan for every person using a GLP-1 medication. Those decisions should be individualized, particularly for people with medical conditions or complex obesity treatment needs.
Are Scientists Developing Drugs Specifically to Preserve Lean Mass During GLP-1 Weight Loss?
Yes, and this has become one of the most interesting new areas in obesity medicine.
The Phase 2 EMBRAZE trial tested tirzepatide together with apitegromab, an investigational antibody designed to inhibit activation of myostatin, a signaling protein involved in regulating skeletal-muscle growth. The randomized, double-blind, placebo-controlled trial enrolled 102 adults with overweight or obesity.
At 24 weeks, participants receiving apitegromab with tirzepatide retained significantly more lean mass than those receiving tirzepatide with placebo while achieving similar overall weight loss. Researchers reported approximately 54.9% relative retention of lean mass with the studied apitegromab regimen. [8]
This is meaningful randomized clinical evidence that lean-mass preservation during incretin-driven weight loss can be influenced pharmacologically. It is not evidence for a consumer treatment protocol, and apitegromab remains investigational for this use.
Is Apitegromab a Muscle-Preservation Drug People Can Add to Ozempic or Zepbound?
No approved obesity treatment currently follows that model.
The EMBRAZE results represent Phase 2 proof of concept. [8] Phase 2 evidence can establish biological and clinical potential, but it does not make a therapy broadly available or approved for a new indication.
Apitegromab is also being developed in other disease areas, but regulatory activity in a separate indication does not make it an approved lean-mass-preservation treatment for people taking tirzepatide or semaglutide.
This distinction is especially important because emerging pharmaceutical research can quickly become consumer interest before the regulatory and clinical evidence is mature. A promising trial should not be converted into a self-directed treatment stack.
What About Bimagrumab?
Bimagrumab is another investigational therapy being studied in this field. It acts through activin type II receptor signaling and should not be described simply as another selective myostatin inhibitor.
A registered clinical trial is evaluating tirzepatide together with bimagrumab and comparing that combination with individual treatment arms. The trial includes DXA lean mass among its primary body-composition outcomes. [9]
At this stage, the trial's existence demonstrates scientific and commercial interest. It does not demonstrate efficacy, and results have not established bimagrumab as a consumer strategy for preserving lean mass during GLP-1 treatment.
Could Peptides or Apelin Prevent GLP-1 Muscle Loss?
There is not enough human therapeutic evidence to support that claim.
Apelin is a biologically interesting signaling peptide involved in cardiovascular, metabolic and muscle physiology. Preclinical research provides a rationale for studying it, but human observational studies examining circulating apelin and sarcopenia have produced mixed findings. A 2025 study of 237 community-dwelling older adults found no significant association between circulating apelin and muscle mass, strength, performance, or sarcopenia status. [10] A separate 2025 paired case-control study of 80 sarcopenic and 80 non-sarcopenic older adults reported significantly lower circulating apelin among sarcopenic participants. [11]
Those studies examine associations between naturally occurring apelin levels and muscle status. They do not test an apelin-based therapy as a treatment for GLP-1-related lean-mass loss. That distinction is important because an emerging biological target can easily be turned into an unsupported consumer peptide protocol long before therapeutic evidence exists.
Does Weight Loss Itself Cause Lean-Mass Loss?
Often, yes.
This is one of the most important contextual findings from the 2026 meta-analysis. People undergoing substantial lifestyle-driven weight loss can also lose lean mass. [5] The proportion varies depending on the intervention, with resistance-training-inclusive programs appearing to preserve lean mass more effectively than approaches without resistance exercise. [5]
This suggests that the current GLP-1 muscle debate should not be framed as medication versus no muscle loss. A more useful comparison is between different ways of losing substantial weight and the strategies available to preserve muscle during that process.
Are Older Adults at Greater Risk?
Potentially. Older adults already face age-related declines in muscle mass, strength and physical performance. Additional loss of functional tissue during major weight reduction may therefore deserve particular attention in this population.
At the same time, obesity itself can impair mobility, metabolic health and physical function, and reducing excess fat can produce major health benefits. The balance is therefore individualized. For an older person with obesity and already-low strength, preserving muscle may be a particularly important component of treatment planning. For another person with severe obesity and high absolute lean mass, some reduction in lean tissue during substantial fat loss may not represent the same degree of clinical concern.
This is another reason functional measurements matter alongside body composition.
Should People Stop Taking GLP-1 Drugs Because of Muscle-Loss Concerns?
The evidence does not support a blanket recommendation like that.
GLP-1-based and incretin therapies have demonstrated substantial benefits for weight reduction and metabolic disease in appropriately selected patients. Lean-mass changes are one part of a broader risk-benefit discussion.
Someone concerned about muscle or strength should discuss those concerns with the clinician managing treatment rather than abruptly changing a prescribed medication based on a social-media claim. A useful clinical discussion may include body-composition trends, strength, physical function, nutrition, exercise, age and baseline sarcopenia risk.
The objective is not simply to achieve the lowest body weight possible. It is to improve health while preserving useful physical function.
The Real GLP-1 Muscle Story Is More Complicated Than "Muscle Melting"
The phrase "muscle melting" is memorable because it is frightening, but it does not describe the current evidence accurately.
Semaglutide, tirzepatide and related therapies can produce substantial weight loss, and some of that weight can come from lean tissue. That is a legitimate clinical issue and deserves attention. At the same time, most weight lost is still fat, lean-mass loss also occurs during major lifestyle-driven weight loss, resistance training appears to improve lean-mass preservation, and muscle strength can improve even while DXA-measured lean mass declines.
Pharmaceutical researchers are also beginning to test therapies designed specifically to preserve lean mass during incretin treatment, suggesting that body composition will become an increasingly important part of future obesity care.
The science is not telling clinicians or patients that muscle does not matter. It is telling them that muscle needs to be measured more intelligently. A scale measures body weight. DXA estimates body-composition compartments. Imaging can estimate skeletal muscle more directly. Strength testing measures what that muscle can do, while physical-performance testing measures what the person can do.
Those are different questions, and the future of obesity treatment is likely to pay much more attention to all of them.